Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
05:23pNovartis AG given CHF 80 PT by Goldman Sachs Group, Inc. (The). neutral ratin.. 
05:21pNovartis division closing Broomfield operations: Broomfield Enterprise, Color.. 
03:15pPharmalot.. Pharmalittle.. Good Morning.. Novartis closing a generic plant &a.. 
01:10pNovartis AG $NVS Set to Announce Earnings on Tuesday  
12:13pForeign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMoti.. 
06:50aNovartis to close 450-employee Sandoz plant in Broomfield
2
12:40aDrugmaker Novartis to close 450-employee Sandoz plant in Broomfield
1
10/16450 jobs will be lost in shutdown of #Novartis division in Broomfield.
4
10/16#2 today Roche ties a $387M knot with Warp Drive Bio in collaboration spotlig..
5
10/16Big #pharma firm Roche, will pay up to $87 million for access to novel natura..
7
10/16[email protected] trial validates #inflammasome as chronic disease driver
12
10/16Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new.. 
10/16Roche Holding's buy rating reiterated at J P Morgan Chase & Co.  
10/16Luxor Announces Paul Roche as President  
10/16Novartis AG given CHF 100 PT by Jefferies Group LLC. buy rating.  
10/16Roche Holding given CHF 295 PT by Jefferies Group LLC. buy rating.  
10/16Roche ties a $387M knot with Warp Drive in collaboration spotlighting new cla.. 
10/16Roche links with Warp Drive Bio in antibiotics deal  
10/16Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new..
12
10/16Roche’s Alecensa wins EU panel’s nod against mutated lung cancer | Pharma Mag.. 
10/16Roche taps Warp Drive to discover novel antibiotic classes in $387M pact
2
10/16Roche taps Warp Drive to discover novel antibiotic classes in $387M pact:
11
10/16Roche Holding given CHF 260 PT by Credit Suisse Group. neutral rating.  
10/16#UCBerkeley deal showcases #biotech @Novartis' new focus on #academic tie-ups.. 
10/15Farmers National Bank Decreases Holdings in Novartis AG $NVS  
10/15Novartis AG $NVS Holdings Maintained by Atlantic Trust LLC  
10/15Novartis charged much MORE for same #drugs the in U.S.A. than in other countr.. 
10/15'Double whammy' for Roche as manufacturing patent losses loom: Reuters  
10/15Novartis AG $NVS Stake Lessened by Wealthsource Partners LLC  
10/15UBS Asset Management Americas Inc. Purchases 952 Shares of Novartis AG $NVS  
10/141st Global Advisors Inc. Sells 610 Shares of Novartis AG $NVS  
10/14Belleville board OKs plans for former Roche site  
10/14Novartis AG $NVS Getting Somewhat Favorable News Coverage, Accern Reports  
10/14Roche's Alecensa wins EU panel's nod against mutated lung cancer  
10/13With Roche's loss of 'Cabilly patents' more than $600M in royalties dissipate..
2
10/13Roche's Alecensa wins EU panel's nod against mutated lung cancer  
10/13No sale for Novartis' $14B Roche stake, but the revamp's not done
1
10/13Roche Ireland runs up further losses following €130m writedown
1
10/13Roche's loss of 'Cabilly patents' will cost it more than $600M
1
10/13$NVS - Linscomb & Williams Inc. Buys New Stake in Novartis AG #NVS  
10/13Roche's Alecensa wins EU panel's nod against mutated lung cancer
1
10/13ZURICH (Reuters) – Swiss drugmaker Roche’s Alecensa has been recommended for .. 
10/13Roche's Alecensa wins EU panel's nod against mutated lung cancer
3
10/13Roche's Alecensa wins EU panel's nod against mutated lung cancer  
10/13Roche's Alecensa wins EU panel's nod against mutated lung cancer  
10/13No sale for Novartis' $14B Roche stake, but the revamp's not done: Fierce Pha.. 
10/13Roche’s skin cancer drug Erivedge pulled from CDF  
10/13#UCBerkeley deal showcases #biotech @Novartis' new focus on #academic tie-ups.. 
10/12'Double whammy' for #Roche as manufacturing #patent losses loom  
10/12Roche's Blockbuster Oncology Drugs Losing Steam As They Approach Patent Expir.. 
10/12No sale for Novartis' $14B Roche stake, but the revamp's not done
1
10/12Sunbelt Securities Inc. Has $418,000 Stake in Novartis AG $NVS  
10/12Trending: No sale for Novartis' $14B Roche stake
1
10/12$PTCT advances SMA program into pivotal portion of SUNFISH study, triggering .. 
10/12Global In-Vitro Diagnostics (IVD) Market Analysis & Outlook 2017-2021 Fea.. 
10/12Novartis puts $14B Roche stake back in its pocket
4
10/12- @Novartis brings leading #BreastCancer doctors together in #Saudi Arabia
1
10/12'Double whammy' for Roche as manufacturing patent losses loom  
10/12PTC Therapeutics earns $20M milestone from Roche on advancement of SMA candid.. 
10/12'Double whammy' for Roche as manufacturing patent losses loom
1
10/12'Double whammy' for Roche as manufacturing patent losses loom  
10/12: Pharmaceutical giant Novartis aims for service as its “north star” via  
10/12Novartis AG given CHF 90 PT by HSBC Holdings plc. buy rating.  
10/12Reminder: Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Confere.. 
10/12Colton Roche: Huddersfield Giants sign Bradford Bulls forward  
10/12Roche Holding given CHF 325 PT by Goldman Sachs Group, Inc. (The). buy rating.. 
10/12#Novartis decides not to sell #Roche stake chairman tells newspaper
1
10/11$NVS: Novartis AG will not sell its stake in Roche Hldg. (RHHBY) according to..
1
10/11UPDATE: Funeral service set for Former Gates Police Chief Thomas Roche
1
10/11EagleClaw Capital Managment LLC Holds Stake in Novartis AG $NVS  
Next »
Qtime:365
Financials ($)
Sales 2017 48 768 M
EBIT 2017 11 713 M
Net income 2017 7 272 M
Debt 2017 17 716 M
Yield 2017 3,29%
P/E ratio 2017 25,59
P/E ratio 2018 21,86
EV / Sales 2017 5,02x
EV / Sales 2018 4,79x
Capitalization 227 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 0,92%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.23%226 956
JOHNSON & JOHNSON18.42%365 346
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
MERCK AND COMPANY7.68%172 751
AMGEN25.17%132 728